MESTAG THERAPEUTICS LTD

12466144
Active Saffron Walden

Research and experimental development on biotechnology

42 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
M

MESTAG THERAPEUTICS LTD

12466144

Research and experimental development on biotechnology

Founded 17 Feb 2020 Active Saffron Walden, England 42 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology

Previous Company Names

BIOTECH 3 LTD 17 Feb 2020 — 27 Mar 2020
Accounts Submitted 11 May 2026 Next due 30 Sept 2026 3 months remaining
Confirmation Submitted 19 Mar 2026 Next due 1 Mar 2027 8 months remaining
Net assets £-32M £16M 2024 year on year
Total assets £29M £16M 2024 year on year
Total Liabilities £61M £32M 2024 year on year
Charges 2
2 satisfied

Contact & Details

Contact

Registered Address

Suites 15 & 16, Science Village Chesterford Research Park Little Chesterford Saffron Walden CB10 1XL England

Website

www.example.com

Full company profile for MESTAG THERAPEUTICS LTD (12466144), an active life sciences and medical technology company based in Saffron Walden, England. Incorporated 17 Feb 2020. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type small
Next accounts 31 Dec 2025
Due by 30 Sept 2026 3 months remaining

Net Assets, Total Assets & Total Liabilities (2020–2024)

Cash in Bank

£23.58M

Increased by £14.03M (+147%)

Net Assets

-£31.66M

Decreased by £16.07M (-103%)

Total Liabilities

£60.98M

Increased by £31.85M (+109%)

Turnover

N/A

Employees

42

Increased by 9 (+27%)

Debt Ratio

208%

Decreased by 7 (-3%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
31 Dec Year End
2023
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 3

Investors (6)

Investor NameInvestor SinceParticipating Rounds
Investor 4Apr 2021Seed
Investor 6Apr 2021Seed
Investor 2Aug 2021Seed

Share Capital

Share Capital

Share allotments and capital structure

22 Allotments 47,436,006 Shares £591104379.37m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
12 Mar 202622,500£0.225£0
12 Mar 202611,700£1.17£0
16 Feb 202614,049£1.405£0
22 Dec 202514,063£1.406£0
31 Oct 202536,871£3.687£0

Officers

Officers

2 active 1 resigned
Status
Dunn, CharlesDirectorBritishEngland3529 Jun 2023Active
Rozen, IssiDirectorAmericanUnited States5916 Jul 2021Active

Shareholders

Shareholders (48)

Johnson & Johnson Innovation - Jjdc, Inc
24.3%
11,531,706
Forbion Capital Fund V Cooperatief U.a
19.9%
9,444,444

Persons with Significant Control

Persons with Significant Control (1)

1 Active 1 Ceased

Johnson & Johnson

Unknown

Active
Notified 14 Oct 2024
Nature of Control
  • Ownership Of Shares 25 To 50 Percent

Sv7 (imf) Gp Llp

Ceased 16 Jul 2021

Ceased

Group Structure

Group Structure

No group structure identified

Charges

Charges

2 satisfied

Properties

Properties

3 leasehold 3 total
AddressTenurePrice PaidDate Added
Suite 15, Science Village Building, Chesterford Park, Little Chesterford, Saffron Walden UTTLESFORD
Leasehold£129,7561 Oct 2024
Suite 16, Science Village Building, Chesterford Park, Little Chesterford, Saffron Walden UTTLESFORD
Leasehold£131,2081 Oct 2024
Suite 2, Science Village Building, Chesterford Park, Little Chesterford, Saffron Walden UTTLESFORD
Leasehold£131,2081 Oct 2024
Suite 15, Science Village Building, Chesterford Park, Little Chesterford, Saffron Walden
Leasehold £129,756
Added 1 Oct 2024
District UTTLESFORD
Suite 16, Science Village Building, Chesterford Park, Little Chesterford, Saffron Walden
Leasehold £131,208
Added 1 Oct 2024
District UTTLESFORD
Suite 2, Science Village Building, Chesterford Park, Little Chesterford, Saffron Walden
Leasehold £131,208
Added 1 Oct 2024
District UTTLESFORD

Documents

Company Filings

DateCategoryDescriptionDocument
1 Jun 2026CapitalAllotment of shares (GBP 4,739.8895) on 12 Mar 2026
11 May 2026AccountsAnnual accounts made up to 31 Dec 2025
24 Mar 2026OfficersAppointment of Mr Charles Dunn as director
19 Mar 2026Confirmation StatementConfirmation statement made on 15 Feb 2026 with updates
17 Mar 2026OfficersAppointment of Mr Charles Dunn as director
1 Jun 2026 Capital

Allotment of shares (GBP 4,739.8895) on 12 Mar 2026

11 May 2026 Accounts

Annual accounts made up to 31 Dec 2025

24 Mar 2026 Officers

Appointment of Mr Charles Dunn as director

19 Mar 2026 Confirmation Statement

Confirmation statement made on 15 Feb 2026 with updates

17 Mar 2026 Officers

Appointment of Mr Charles Dunn as director

Recent Activity

Latest Activity

Allotment of shares (GBP 4,739.8895) on 12 Mar 2026

1 weeks ago on 1 Jun 2026

Annual accounts made up to 31 Dec 2025

1 months ago on 11 May 2026

Appointment of Mr Charles Dunn as director

2 months ago on 24 Mar 2026

Confirmation statement made on 15 Feb 2026 with updates

2 months ago on 19 Mar 2026

Appointment of Mr Charles Dunn as director

2 months ago on 17 Mar 2026